Anzeige
Mehr »
Dienstag, 26.08.2025 - Börsentäglich über 12.000 News
Breaking: AlsetAI zündet nächste Stufe - Neue Allianz mit CHIP Datacentres & Hochkarätige Vorstände markieren Wendepunkt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1XA9J | ISIN: FI4000074984 | Ticker-Symbol: 2VO
Tradegate
26.08.25 | 11:49
29,710 Euro
-0,64 % -0,190
1-Jahres-Chart
VALMET OYJ Chart 1 Jahr
5-Tage-Chart
VALMET OYJ 5-Tage-Chart
RealtimeGeldBriefZeit
30,02030,08017:00
30,03030,07017:00
PR Newswire
181 Leser
Artikel bewerten:
(1)

Valmet Oyj: Valmet to deliver an IntelliTissue 1600 machine to PT Suparma Tbk in Indonesia

Valmet Oyj's press release on August 25, 2025, at 9:30 a.m. EEST

ESPOO, Finland, Aug. 25, 2025 /PRNewswire/ -- Valmet will deliver an IntelliTissue 1600 tissue machine to PT Suparma Tbk's mill in Surabaya, Indonesia. The new installation will enable production of high-quality tissue products for the Asia Pacific market and the start-up is planned for 2026.

The order was included in Valmet's orders received of the second quarter 2025. The value of the order will not be disclosed.

Valmet and PT Suparma Tbk have a long history of partnership, including several tissue projects. The most recent delivery was an IntelliTissue machine (TM10) installed at the same mill and started up in 2022.

"It is a pleasure to expand our cooperation with Valmet through our new Tissue Machine investment. We chose Valmet as the supplier for our milestone project due to their good understanding of our specific needs, and the excellent collaboration between our teams demonstrated during the previous project. Undoubtedly, we wish to grow our partnership further in the future," says Joseph Sulaiman, Director, PT Suparma Tbk.

"We have a long and successful history of co-operation with PTSuparma Tbk. We are proud to once again have gained their trust to supply the reliable and resource efficient IntelliTissue concept and work together enhancing their continued tissue expansion. I am convinced that this will be another efficient project and smooth start-up together," says Pemo Klimczak, Vice President, SMM business unit, Valmet.

Technical information about the delivery
The delivery will comprise a complete tissue production line, including stock preparation equipment. The new line will feature an IntelliTissue 1600 machine equipped with an IntelliJet V headbox, Crescent Former, IntelliPress, IntelliYankee dryer, Exhaust Cap hood, and an IntelliReel section.

The scope also includes mechanical and electrical drives, Valmet DNA system with Machine Control System, Distributed Control System and Quality Control System, dust removal system, and auxiliary systems for the tissue line. The tissue line will add an additional 26,500 annual tons of tissue paper to Pt. Suparma Tbk's current production capacity.

About the customer, PT Suparma, Tbk

PT Suparma, Tbk, established in 1976 in Surabaya, Indonesia is a leading paper and tissue manufacturer dedicated to providing reliable and high-quality products. The company is focusing on continuous improvement, product innovation and environmentally friendly production. PT. Suparma, Tbk utilizes recovered fibers for most of its products. The company serves both national and international markets, meeting diverse customer needs with a wide range of paper products.

VALMET
Corporate Communications

Further information:
Przemyslaw Pietrzyk, Sales Manager, Tissue business area, Valmet, tel. +48 694 445 263

Valmet is a global technology leader serving process industries. We work together with our customers throughout the entire lifecycle, delivering cutting-edge technologies and services as well as mission-critical automation and flow control solutions. Backed by more than 225 years of industrial experience and a global team of over 19,000 professionals close to customers, we are uniquely positioned to transform industries toward a regenerative tomorrow.

In 2024, Valmet's net sales totaled approximately EUR 5.4 billion. Our head office is in Espoo, Finland, and we have experts in approximately 40 countries around the world. Valmet's shares are listed on Nasdaq Helsinki.

Follow us on valmet.com | X | X (IR) | LinkedIn | Facebook | YouTube | Instagram |

Processing of personal data

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/valmet-oyj/r/valmet-to-deliver-an-intellitissue-1600-machine-to-pt-suparma-tbk-in-indonesia,c4222436

The following files are available for download:

https://news.cision.com/valmet-oyj/i/4222436-0-jpeg,c3462826

4222436_0.jpeg

Cision View original content:https://www.prnewswire.co.uk/news-releases/valmet-to-deliver-an-intellitissue-1600-machine-to-pt-suparma-tbk-in-indonesia-302537481.html

© 2025 PR Newswire
Tech-Aktien mit Crash-Tendenzen
Künstliche Intelligenz, Magnificent Seven, Tech-Euphorie – seit Monaten scheint an der Börse nur eine Richtung zu existieren: nach oben. Doch hinter den Rekordkursen lauert eine gefährliche Wahrheit. Die Bewertungen vieler Tech-Schwergewichte haben historische Extremniveaus erreicht. Shiller-KGV bei 39, Buffett-Indikator auf Allzeithoch – schon in der Dotcom-Ära war der Markt kaum teurer.

Hinzu kommen euphorische Anlegerstimmung, IPO-Hypes ohne Substanz, kreditfinanzierte Wertpapierkäufe in Rekordhöhe und charttechnische Warnsignale, die Erinnerungen an 2000 und 2021 wecken. Gleichzeitig drücken geopolitische Risiken, Trumps aggressive Zollpolitik und saisonale Börsenschwäche auf die Perspektiven.

Die Gefahr: Aus der schleichenden Korrektur könnte ein rasanter Crash werden – und der könnte vor allem überbewertete KI- und Chipwerte hart treffen.

In unserem kostenlosen Spezial-Report zeigen wir Ihnen, welche Tech-Aktien am stärksten gefährdet sind und wie Sie Ihr Depot vor dem Platzen der Blase schützen könnten.

Holen Sie sich den neuesten Report!

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.